Abstract: Noninvasive,real-time pharmacokinetic (PK) monitoring of ketamine,p ropofol, and valproic acid, and their metabolites was achieved in mice,using secondary electrospray ionization and high-resolution mass spectrometry.T he PK profile of ad rug influences its efficacy and toxicity because it determines exposure time and levels.T he antidepressant and anaesthetic ketamine (Ket) and four Ketm etabolites were studied in detail and their PK was simultaneously determined following application of different sub-anaesthetic doses of Ket. Bioavailability after oral administration vs.i ntraperitoneal injection was also investigated. In contrast to conventional studies that require many animals to be sacrificed even for lowresolution PK curves,this novel approach yields real-time PK curves with ah itherto unmatched time resolution (10 s), and none of the animals has to be sacrificed. This thus represents amajor step forwardnot only in animal welfare,but also major cost and time savings.
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Current drug discovery programs rely heavily on the characterization of compounds with unknown in vivo properties using animal models prior to the clinical phases of development. [1] During lead optimization, pharmacokinetic (PK) parameters of each compound are determined in plasma and possibly in specific target organs of mice and rats.B y determining the concentration of each compound and its degradation products over time in agiven tissue,itispossible to estimate exposure levels after administration of ag iven dose.However,since each time point in aPKprofile typically requires the sacrifice of several animals,l arge amounts of compound have to be synthesized and potentially significant interindividual variation is encountered. Therefore,i tw ould be highly desirable to achieve such time-resolved analyses in individual animals.A ided by the development of highly sensitive bioanalytical methods,d ried blood spot and microsampling techniques have been introduced recently to overcome some of these limitations. [2] Especially in mice this significantly reduces the number of animals and amount of compound needed, and prevents interindividual variation.
Microsampling of blood at the tail, however, has the drawback of stressing the animal, which may change drug distribution and metabolism. [3] Although this problem can be overcome by using,for example,more invasive implanted catheters for automated sampling systems, [4] the solution is far from ideal. Despite advances in high-throughput analyses by chromatographic and mass spectrometric methods,s ubstantial time and effort are needed for sample preparation and analysis.Current methods thus still require significant resources,a nd are far from providing an instantaneous response to determine whether acandidate drug fulfills the requirements for further consideration.
Mouse breath could provide am atrix to overcome these limitations.Monitoring breath has received significant attention since the 1970s due to its noninvasive character. [5] Compared to the analysis of plasma, blood, and other biosamples,a nalysis of breath is advantageous because: 1) the sampling is minimally invasive or noninvasive; 2) there is no or little restriction on sampling volume and frequency;3 )the matrix is relatively simple and clean. Noninvasive,r eal-time,o n-line,a nd direct analyses can therefore be readily achieved in breath. [6] Here we report that secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS) can be used to determine the PK profile of drugs noninvasively and in real time. [7] .D ue to its sensitivity and its capability of detecting higher-mass drugs and their metabolites,S ESI has important advantages over proton-transfer-reaction MS, which can monitor endogenous breath compounds in rats and mice. [8] In this study,w ei nvestigated the pharmacokinetics of different drugs,i ncluding ketamine (Ket) and its metabolites in the breath of male C57Bl/6J mice.K etamine, an NMDAr eceptor antagonist, has been developed as ag eneral anesthetic but is mostly used as an analgesic for severe pain and lately has shown some promise in the treatment of depression. [9] After administration of the drug, animals were placed in an acrylic chamber flushed with ac onstant flow of air, which was then directly analyzed by SESI-HRMS ( Figure 1a ,F igure S1, and Experimental Section).
To verify that Ket injection did not influence the drug measurements through mediating changes in respiration, we used whole-body plethysmography.W ef ound no significant difference to reported values of minute volume for B6 mice (ca. 70 mL min À1 ), [10] and Ket injection had no significant impact on the minute volume (data not shown).
Shortly after Ket administration to mice,weobserved the increase of as ignal cluster in the range m/z 238-240, which perfectly matched the isotopic distribution of the protonated molecule ( (Figure 1b) . Furthermore,f ragment ions formed from the [M + H] + ion of Ket (Figure 1c ) matched those previously reported, [11] and fragments obtained from Ket standard (Figure S2 a) . Not only Ket, but also its main metabolites could all be detected with our setup. Norketamine (NK) [11, 12] was unambiguouslyi dentified in mouse breath ( Figures S2 ba nd S3 a) . Three further metabolites of Ket were simultaneously detected (Figures S3 and S4): hydroxyketamine (HK), hydroxynorketamine (HNK), and dehydronorketamine (DHNK). [13] Administration of multiple sub-anaesthetic doses of Ket led to concentration distributions similar to those previously reported, with ah alf-life (t 1/2 )o f2 3min (Figures 2a and S5) , which agrees well with values obtained from plasma. [14] Note that aprecise comparison between breath and plasma values would require very frequent plasma sampling, which is difficult or impossible with current methodologies due to volumetric constraints.
To estimate the biological variability of our method, we tested an additional batch of three mice injected with 45 mg kg À1 Ket ( Figure S6 ). Va riation of the maximum Ket signal intensity (I max )w as roughly 18 %. If one considers an increase in dose from 45 to 60 mg kg À1 ,w hich resulted in an 86 %i ncrease in I max (i.e.f rom 2.4 10 5 to 4.4 10 5 counts in Figure 2a ), this demonstrates that our method gives arobust and reproducible reading of drug levels.
We found an almost linear correlation of I max and the injected drug concentration (Figure 2b) , which is also consistent with the plasma behavior reported for Ket. [15] However, I max was found to be delayed when compared to plasma values obtained from the literature. [14] This phenomenon could be attributed to the partitioning of Ket (and also its metabolites) between the blood and breath. [16] Compared to earlier studies,b reath profiles of Ket and its metabolites coincide more closely with those expected for organ levels than for plasma;f or example,K et peaks 10-20 min in the liver,s kin, and muscle after i.v.i njection in rats. [17] Thus,i ti s likely that breath analysis reports lung levels rather than plasma levels.S ince most drugs target organs rather than blood itself,t his kinetic difference could be significant and useful, and represents another potential advantage of breath analysis.
Similarly to Ket, its four metabolites showed al inear dose-response trend for I max ( Figure S7 ). As expected, the primary metabolites (i.e., NK and HK) peaked after Ket, which is consistent with results reported for NK in rat serum samples. [13] Although NK and HK have the same t max ,t hey showed as imilar decay at ad ose of 15 mg kg À1 ,b ut very different decay at increasing dose (i.e.NKdropped at higher rate than HK;F igure S8).
Secondary NK metabolites (i.e., HNK and DHNK) peaked well after NK. Overall, it was consistently found at different doses that t max (Ket) < t max (NK) % t max (HK) < t max (HNK) % t max (DHHK) (Figures 3a,S 7 , and S9), while I max (HK) < I max (DHNK) < I max (HNK) < I max (NK) < I max (Ket) (Figure 3b) . . .
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To study the relationship between the known plasma PK and that of our novel matrix, we compared the intensity of Ket and NK recorded in breath with the plasma concentrations from the same animal at that moment in time by terminal blood sampling (Figure 3c ). Asignificant correlation was observed between breath and plasma levels for Ket (r 2 = 0.9498, p-value = 0.0254) and NK (r 2 = 0.9739, p-value = 0.0131). Thec oncentrations in plasma depended on when the animals were sacrificed after Ket administration. Thedata in Figure 3c were obtained 32, 40, and 58 min after Ket administration of 15, 30, and 45 mg kg À1 ,respectively.Atthis time,K et had already started to be metabolized and redistributed to different body compartments,w hich why the concentration of NK is plasma is higher than that of Ket. In contrast, the peak intensity of NK in exhalation was only around one-fifth of that of Ket (Figure 3b) . Likely,t his reflects the partitioning of Ket between blood and breath. [16] It may well be that breath levels reflect organ concentrations: the transport of NK from blood into the lung and breath should be less efficient than that of Ket due to the lower lipophicility of NK. This has been found for the blood-tobrain transport efficiencyo fN K, which is inferior to that of Ket. [13] However,f urther direct comparisons with LCMS experiments on tissues would be needed to confirm this hypothesis.I na ddition, while translating ion intensity into absolute gas-phase concentrations is possible, [18] it is instrument-and compound-dependent. In this study,w er eport on ion intensity,r ather than absolute gas-phase concentrations.
In order to strengthen the potential of this technique for in vivo real-time drug studies,w em easured PK curves for additional drugs:p ropofol (a widely used anesthetic) and valproic acid (an antiepileptic drug). Figure S10 shows the isotopic distribution of propofol along with its fragmentation spectrum. TheP Kc urve is shown in Figure S11 , which is consistent with the literature. [19] Similarly,t he PK curve of valproic acid and one of its metabolites ( Figure S12 ) was found to be consistent with reported values. [20] Moreover,w ef urther explored the possibility to rapidly estimate not only drug PK, but also bioavailability after oral dosing,because this is strongly preferred in most indications.
Ty pically,this is tested early during drug discovery when only precious little compound is available.T herefore,w et ested whether we could use our method to estimate oral bioavailability and compared the oral dosing of ketamine to IP dosing ( Figure S13 ). We found an I max for the oral dose of around 15 %o ft hat of the IP administration. This is consistent with literature in rats and humans. [21] In conclusion, we show SESI-HRMS analysis of mouse breath to be apromising strategy for minimally invasive,realtime pharmacokinetic monitoring using Ket, propofol, valproic acid, and their metabolites as examples.P erhaps the most significant advantage of the presented breath analysis method is that pharmacokinetic data based on mass spectrometric monitoring of exhalation is available instantaneously in real time and with superior time resolution from as ingle individual. Thus,o ur methodology not only results in more precise data with considerable time and cost savings,but also represents an important step forward in improving animal welfare,s ince multiple compounds can easily be measured repeatedly in as ingle animal. Thef act that the proposed method makes it possible to obtain acomplete PK curve with one single dose/animal may be advantageous when small quantities of compound are available in preclinical studies. Furthermore,d rug/drug-interaction studies can be easily monitored, even if the compounds have completely different dosing schedules and kinetics.A sa ni mportant secondary advantage,weh ypothesize that pharmacokinetic profiles are obtained that reflect tissue rather than plasma levels.
We are confident that the SESI-HRMS method will be useful in preclinical programs and may even have potential applications in the clinical phases of drug development. [7] Keywords: breath analysis ·high-resolution mass spectrometry · ketamine ·pharmacokinetics ·secondary electrospray ionization 
